NEW YORK--(BUSINESS WIRE)--DermaPlus, Inc. is offering research quantities of its laboratory synthesized human Tropoelastin to qualified organizations engaged in organ and tissue regeneration research. The Company’s version of Tropoelastin, trademarked Elastatropin, can be used as a cost-effective and reliable scaffold material and connective matrix to bind and reinforce cells when growing cells into organ-like masses. The DermaPlus business model in place is using revenue from their successful DermaLastyl skin cream products to make plentiful quantities of Tropoelastin/Elastatropin available for organ and tissue regeneration research.
